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Medication At discharge At 1 -year follow-up p value 
ASA 93% 83% <0.001 
Beta-blockers 77% 66% <O.OOl 
ACE inhibitors 56% 55% NS 
ARBs 3.3% 7.5% CO.001 
Lipld lowering agents 57% 68% <O.OOl 
The rates and trends for medication use were similar irrespective of the index discharge 
ACS diagnosis. 
Conclusions: While the use of acetylsalicylic acid (ASA) and beta-blockers was high at 
discharge, It declined significantly at l-year follow-up. In contrast, the use of angiotensin 
converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARES), and lipid low- 
erlng agents was sustained or increased. While the reasons for medication discontinua- 
tlon are unknown, there appears to be a significant opportunity to improve on the 
adherence to ewdence-based therapies. 
Table I 
Reocclusion 
l-year deathlreinfarction 
Women Man OR (95% Cl) 
20% 19% 1.10 (0.56-2.12) 
1 1% 11% 0.98 (0.40-2.29) 
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TIMI flow is a predictor of prognosis after acute myocardial infarction (AMI). Lesion mor- 
phology that determines TIMI flow has not been studied in detail, especially using intra- 
vascular ultrasound (IVUS). We therefore analyzed pre-intervention IVUS and 
angiography in 97 AMI pts who presented <72hrs from symptom onset. Forty-four pts 
(45.4%) received intravenous thrombolysis before IVUS. Because AMI lesions typically 
include thrombi, qualitative IVUS assessment focused on thrombus-related morpholo- 
gies: channels Into the plaque, bright-speckled elements, hypoechoic masses, and 
absence of an evacuated plaque cavity. Measurements included lesion and reference 
artery, lumen and plaque (artery-lumen) areas. Remodeling index was calculated as 
lesion/mean reference artenal area. Results: There were no significant differences in pt 
and vessel characteristics or history of thrombolysis among the 3 TIMI flow grade groups. 
IVUS results are shown in the table. Conclusion: TIMI flow in pts following AMI is related 
to plaque characteristics as determined by IVUS. In particular, evidence of thrombus 
(strongest in TIMI O/I and weakest in TIMI Ill), lesion length and positive remodeling, but 
not residual lumen, affect TIMI flow. 
Background:The Clopldogrel in Unstable Angina to Prevent Recurrent Events (CURE) 
trial Economic Analysis demonstrated the incremental cost-effectiveness of clopidogrel 
therapy in patients with non-ST segment elevation acute coronary syndrome (ACS). The 
purpose of the current analysis is to assess the cost-effectiveness of clopidogrel in the 
large subgroup (N=2658) of patients undergoing PCI in the CURE trial (PCI-CURE 
study). 
Methods: Cost effectiveness was assessed in 5 countries, including the United States, 
United Kingdom, France, Sweden and Canada based upon the results of the PCI-CURE 
study. We calculated the costs of hospitalization, medication and study drug based on 
resource utilization for all patients undergoing PCI in the CURE study. Unit costs were 
derived from both Medstat and Medicare, representing both insurance and governmental 
payment systems in the United States. Cost effectiveness was expressed as the cost per 
event avoided. 
Results: Data to date are available for Sweden and France. Patients in the clopldogrel 
arm have on average higher costs than patients treated with ASA alone, 9,947 Euros 
compared to 9,817 Euros in Sweden and 6,465 Euros compared to 8,213 Euros; in 
France. The net cost is 130 and 252 Euros; in the two countries. The additional cost is 
due to the cost of clopldogrel, which is partly offset by savings during the initial hospital- 
ization. The cost offset was 335 and 152 Euros in Sweden and France, respectively. 
Other costs were similar in both groups. Treatment with clopidogrel led to 0.038 avoided 
events (0.126 events in the ASA arm compared to 0.088 in the clopidogrel + ASA arm). 
This lead to a cost-effectiveness ratio of 3,421 Euroslevent avolded in Sweden and 6,632 
Euro&event avoided in France. 
TIMI-O/I TIMI-II TIMI-III P 
Conclusions: Clopidogrel therapy started acutely and continued for up to one year is 
highly cost-effective in patients wth ACS undergoing PCI. A full cost-effectiveness analy- 
sis pertaining to all 5 countries will be presented in detail. 
Lesion length (mm) 
Lesion plaque area (mm2) 
Lesion plaque burden (%) 
Lesionlumen area (mm2) 
Remodeling index 
Channels wthin plaque (%) 
Brightly speck;ed plaque (%) 
Evacuated plaque cavity (%) 
22*9 16i7 16+10 0.02 
13.6i5.5 13.9a6.0 13.4+6.0 0.98 
85.8&3 85.5i6.8 82.9r13.0 0.84 
1.9io.9 2.2+1 .I 2.5k2.4 0.74 
1.5~0.2 1.1*0.2 1.1*0.2 0.01 
27.3 3.4 4.0 0.03 
72.7 17.2 23.5 0.0004 
0 3.4 22.2 0.03 
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Background: Post thrombolysis, early resolution of ST-segment elevation (STm) pre- 
dicts restoration of TIMI Ill in the infarct-related artery (IRA) with a oositive oredictive ,.. 
value (PPV) of 70.80%. Post successful primary angioplasty (PCI) SflR is a surrogate 
of tissue level reoerfusion. Sl?R after treatment with asolrin in oatients with .Sfl mvo- 
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Background: Female gender is often believed to portend worse outcome after ST-eleva- 
tion myocardial infarction (Ml). Whether this is independently related to gender, or prima- 
rily due to clinical and angiographic differences at baseline is a matter of debate. 
Methods: Patients (n=452) had fibrinolysis for acute ST elevation Ml and an open infarct 
artery at coronary angiography performed within 48 hours. Patients had 3-month follow- 
up angiography and l-year clinical follow-up. 
Results: Of the 452 patients 75 (I 7%) were female. Women were older (59*11 vs. 56+9 
years, p < O.Ol), more often had a history of hypertension (39% vs. 22%, p < 0.01) and 
were more often smokers than men (73% vs. 63%, p=O.O8). Single vessel disease was 
more frequent among women: 69% vs. 54% (p=O.Ol). Baseline stenosis severity (CICA) 
was less severe: 54+14 vs. 5&t3 (p=O.O4). Table 1 shows clinical and angiographic out- 
come. Adjustment for baseline imbalances did not reveal an independent relatlonship 
with gender. 
Conclusions: Despite a less favorable clinical baseline risk-profile, l-year clinical out- 
come after successful fibrinolysis did not differ between men and women. A higher-risk 
angiographic baseline profile was not apparent. and 3-month reocclusion was similar to 
men. These findings challenge the often generalized association between gender and 
OutCOme, and warrant further exploration as to whether other mechanisms drive this rela- 
tionshio. 
cardial infarction (STEMI) has not been investigated, although if r&able may effect 
immediate clinical management. 
Methods: The study comprised 172 consecutive patients assigned to primary PCI for 
STEMI. Patients were treated with chewable aspirin and heparin and the sum of STf 
&STf) was assessed on admission and afterl0-15 minutes of each aspirin dose. The 
patients were urgently catheterized regardless of the changes in SST?. TIMI flow in the 
IRA was determined on the initial and final angiogram. ADP- and epinephrine- induced 
platelet aggregation was determined before catheterization. Patients were followed 
throughout hospitalization. 
Results: Early XSflR 270% was associated with a higher prevalence of patent IRA 
(TIMI 11-111) on initial angiography (94% vs 24%. p<O.Ol) and of TIMI Ill flow (36% vs 6% 
p<O.Ol). IST? resolution 250% was similarly associated with a higher rate of IRA 
patency and TIMI Ill flow (p-zO.01 for both), but with a lower PPV for patency (85% vs 
94%) and for TIMI III flow (32% vs 36%). Patients with (36 [21%]) and without (136 
[79%]) early ZSTTR 2 70% did not differ with respect to aspirin dose (333+89 vs 
313+7lmg, p=O.l3) and use of heparin (85% vs 78%. p=O.8) prior to catheterization. 
age, gender and risk factor distribution. but had lower epinaphrine-induced platelet 
aggiegation (40.4*12% vs 59.5&11%. p=O.O15). Despite similar prevalence of TIMI Ill 
flow at the completion of the PCI (85% vs 83%, p=O.9) patients with SflR had a lower 
incidence of death or CHF (7.8% vs 25.4%, p=O.O5), QMI (42% YS 73%, p-zO.01). lower 
peak CK (750*1071 vs 2389*1854, pcO.Ol), and better LVEF (47+12 vs 42+t 1, p=O.O4). 
Conclusions: In patients with STEMI undergoing primary PCI,ISTTR 270% after aspirin 
treatment is a reliable sign of IRA patency, but not of TIMI Ill flow, and predicts smaller 
myocardial damage and better in-hospital outcome. 
